DEFENCE THERAPEUTICS IS GRANTED PATENTS IN JAPAN AND ISRAEL EXPANDING ITS NOVEL ADC PLATFORM TECHNOLOGY IN THE FAST GROWING ANTIBODY-DRUG CONJUGATES MARKET

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous
DEFENCE THERAPEUTICS IS GRANTED PATENTS IN JAPAN AND ISRAEL EXPANDING ITS NOVEL ADC PLATFORM TECHNOLOGY IN THE FAST GROWING ANTIBODY-DRUG CONJUGATES MARKET
29.09.2022 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

_________________________________________________________________

CSE: DTC  FSE: DTC  USOTC: DTCFF  PRESS RELEASE

DEFENCE THERAPEUTICS IS GRANTED PATENTS IN JAPAN AND ISRAEL EXPANDING ITS NOVEL ADC PLATFORM TECHNOLOGY IN THE FAST GROWING ANTIBODY-DRUG CONJUGATES MARKET

Vancouver, BC, Canada, September 29^th, 2022 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate (“ADC”), is pleased to announce that a notice of allowance has been issued by the Japan Patent Office for its Japanese patent application no. 2018-568469. In addition, the acceptance of its Israeli patent application no. 261765 was published in the Israel Patents and Designs Journal on 1^st August 2022.

The allowance of these new patents covering conjugated compounds permitting delivery of antibodies to the nucleus through the Company proprietary technology Accum^TM. Accum^TM further consolidate the Company’s patent portfolio on its solution for precision delivery method for improved intracellular antibody drug conjugate (“ADC”) routing. Overcoming problematic cell recycling and rejection patterns, Accum™ enables ADCs to control intracellular delivery of chemotherapeutic drugs, resulting in superior preclinical anti-tumor activity. By increasing the tumor targeting specificity – due to increased drug accumulation – non-specific toxicity in healthy cells is greatly reduced.

"The Japan and Israel patents constitute an important milestone in protecting and expanding the commercial potential of Accum^TM directly related to our ADC program. Defence is expecting pending key studies results in the near term and will report as they become available. Defence’s commitment to protect the Company’s Accum^TM technology platform innovation is crucial as its ADC development expands. ADC interest continues to increase worldwide being that ADC’s are applied in oncology and is advancing rapidly", says Mr. Plouffe, the CEO of Defence Therapeutics.

According to Precedence Research Predicts, the global oncology market size is expected to worth around US$ 536.01 billion by 2029 from valued at USD 286.04 billion in 2021 and growing at a CAGR of 8.2% from 2021 to 2030. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Rising concern about the cancer and patient is one of the major factors driving the market for oncology market.

https://www.biospace.com/article/oncology-market-size-to-worth-around-us-536-01-bn-by-2029/

The global antibody drug conjugates market size is expected to reach over USD 22.87 billion by 2030, registering a CAGR of 16.4% during the forecast period, according to a recent 2022 report by Grand View Research Inc. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive the market growth during the forecast period.

https://www.grandviewresearch.com/press-release/global-antibody-drug-conjugates-market

About Defence:

Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM^TM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

Splouffe@defencetherapeutics.com

www.defencetherapeutics.com

Cautionary Statement Regarding “Forward-Looking” Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

29.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com